SCHEMBL4178010

SCHEMBL4178010

COc1cccc(C2CCCN(C(=O)c3csc(NS(=O)(=O)c4ccccc4)n3)C2)c1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TRPC3 Q13507 2/20 0.51
TRPC6 Q9Y210 2/20 0.51
PROKR1 Q8TCW9 1/20 0.49
MYC P01106 1/20 0.49
ALDH1A1 P00352 6/20 0.47
LMNA P02545 2/20 0.47
HPGD P15428 1/20 0.47
HIF1A Q16665 1/20 0.47
GAA P10253 2/20 0.46
SIRT5 Q9NXA8 1/20 0.45
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
PKM P14618 2/20 0.43
KDM1A O60341 2/20 0.43
MAOA P21397 2/20 0.43
GFER P55789 1/20 0.42
HTT P42858 1/20 0.42
BCL9 O00512 1/20 0.41
CTNNB1 P35222 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4176998 0.86 TRPC3 (0.52) TRPC3TRPC6KDM1AMAOA
SCHEMBL4177379 0.86 GAA (0.56) TRPC3TRPC6ALDH1A1LMNAGAA
SCHEMBL4178167 0.84 TRPC3 (0.54) TRPC3TRPC6ALDH1A1HPGD
SCHEMBL4173881 0.84 TRPC3 (0.56) TRPC3TRPC6LMNAHPGDKMT2A
SCHEMBL4177020 0.83 TRPC3 (0.51) TRPC3TRPC6ALDH1A1LMNAHPGD
SCHEMBL4165060 0.83 TRPC3 (0.55) TRPC3TRPC6ALDH1A1LMNAHPGD
SCHEMBL4178536 0.82 TRPC3 (0.42) TRPC3TRPC6ALDH1A1HPGDGAA
SCHEMBL4176042 0.81 ALDH1A1 (0.47) TRPC3TRPC6ALDH1A1LMNAHPGD
SCHEMBL4176879 0.81 ALDH1A1 (0.53) TRPC3TRPC6ALDH1A1GAASIRT5
SCHEMBL3162537 0.80 PROKR1 (0.57) PROKR1MYCALDH1A1LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8357711-B2 Heterocyclic sulfonamides as inhibitors of ion channels PFIZER LIMITED (GB) 2013-01-22 US disclosed
US-20090143358-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143358-A1 INHIBITORS OF ION CHANNELS TRPV1, TRPV5, TRPA1 TRPC3 57/4885TRPC6 84/4885PROKR1 4825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.